Capricor Therapeutics Reports Q4/FY25 Results, Secures Cash Runway, and Advances Deramiocel BLA with August 2026 PDUFA Date

summarizeSummary

Capricor Therapeutics reported Q4 and full-year 2025 financial results, showcasing a strengthened balance sheet with cash runway through 2027, and provided a positive corporate update including an August 2026 PDUFA date for its Deramiocel BLA.

check_boxKey Events

• Strengthened Financial Position

  Cash, cash equivalents, and marketable securities increased to approximately $318.1 million as of December 31, 2025, up from $151.5 million a year prior, extending the cash runway through 2027. This was supported by a $161.9 million public offering and $75.1 million from an at-the-market program in Q4 2025.

• Deramiocel BLA Under FDA Review

  The Biologics License Application (BLA) for Deramiocel in Duchenne muscular dystrophy is under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. This follows the FDA lifting a previously issued Complete Response Letter.

• Positive Phase 3 HOPE-3 Data Reinforced

  The pivotal HOPE-3 Phase 3 trial met its primary and key secondary cardiac endpoints. Late-breaking data presented at MDA 2026 further demonstrated Deramiocel's impact on cardiac and skeletal muscle function, including a significant reduction in myocardial fibrosis.

• Commercial Readiness Progress

  The San Diego GMP manufacturing facility is operational after successfully completing an FDA Pre-License Inspection, with all Form 483 observations addressed, positioning the company for potential commercial launch.

auto_awesomeAnalysis

This 8-K provides a comprehensive update, highlighting significant progress on multiple fronts. The substantial increase in cash, driven by recent offerings, extends the company's financial runway through 2027, which is critical for a biotech nearing commercialization. While operating expenses and net losses have increased, this is typical for a company advancing a late-stage therapeutic. The confirmation of an August 2026 PDUFA date for Deramiocel's BLA, coupled with reinforced positive Phase 3 data and manufacturing readiness, significantly de-risks the path to market for their lead product. The uplisting to Nasdaq Global Select Market also enhances the company's profile. Investors should monitor the FDA review process closely as the PDUFA date approaches.